MCT Index: Multiple Myeloma Trials List
2022
-
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM
-
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
-
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone
-
NCT05396885: Phase 2: iMMagine-1 - Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma
-
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
-
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
-
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
-
NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT
-
NCT05317416: Phase 3: MagnetisMM-7 - Elranatamab Versus Lenalidomide in Patients post ASCT with NDMM
-
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
-
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM
-
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
-
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
-
NCT05272826: Phase 2: BOREALIS - Study of Iberdomide, Bortezomib, and Dexamethasone for NTE - NDMM
-
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
-
NCT05243797: Phase 3: MajesTEC-4 - Tec + Len Vs Len Alone as Maintenance Therapy Post ASCT - NDMM
-
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
-
NCT05228470: Phase 2: MagnetisMM-8 - Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
-
NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
-
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
-
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
-
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
-
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
2021
-
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma
-
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
-
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)
-
NCT05064358: Phase 2 - (DREAMM 14) - Alternative Dosing Regimens of Belantamab Mafodotin RRMM
-
NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT
-
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
-
NCT05066646: Phase 1/2: FUMANBA-1 - Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
-
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART
-
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
-
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
-
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
-
NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
-
NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma
-
NCT05083169: Phase 3: MajesTEC-3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma
-
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone
-
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
-
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
-
The PCROWD Study invites people with precursor conditions to Share samples a few times each year
-
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
-
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
-
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
-
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
-
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
-
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma
-
NCT05016778: Phase 1: POLARIS - (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM
-
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
-
NCT05014412: Phase 1/2: MagnetisMM-9 - Elranatamab in MM That Has Come Back or Has not responded
-
NCT04764942: Phase 1/2: The SCOPE Trial - Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma
-
NCT04998747: Phase 1: (ProxiMMity-1) - A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma
-
FDA Approved RRMM:Daratumumab & Hyaluronidase-fihj + Pomalidomide (Pomalyst) & Dexamethasone
-
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
-
NCT04975997: Phase 3: EXCALIBER-RRMM - IberDd Vs DVd in Relapsed Refractory Multiple Myeloma
-
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
-
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
-
NCT04934475: Phase 3 - IFM 2020-02 - (MIDAS) KRD-Isatuximab- Minimal Residual Disease Adapted Strategy - NDMM
-
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
-
NCT04751877: Phase 3 - IFM 2020-05 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients - NDMM
-
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble - NDMM
-
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma - NDMM
-
NCT04843579: Phase 2: ClaSPd - Selinexor in Combination With Clarithromycin, Pom & Dex RRMM
-
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients - NDMM